Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group

U. Bruntsch; P. Dodion; W.W. ten Bokkel Huinink; H.H. Hansen; H.M. Pinedo; M. Hansen; J. Renard; M. van Glabbeke

Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group

U. Bruntsch
, P. Dodion
, W.W. ten Bokkel Huinink
, H.H. Hansen
, H.M. Pinedo
, M. Hansen
, J. Renard
, M. van Glabbeke

Research output: Contribution to journal › Article › Academic › peer-review

21 Downloads (Pure)

Original language	English
Pages (from-to)	697-699
Journal	European journal of cancer & clinical oncology
Volume	22
Issue number	6
Publication status	Published - 1986

Access to Document

8035Final published version, 225 KB

Cite this

Bruntsch, U., Dodion, P., ten Bokkel Huinink, W. W., Hansen, H. H., Pinedo, H. M., Hansen, M., Renard, J., & van Glabbeke, M. (1986). Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group. European journal of cancer & clinical oncology, 22(6), 697-699.

@article{81ce59a5882f45738abd3bf9ffaf34c1,

title = "Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group",

author = "U. Bruntsch and P. Dodion and \{ten Bokkel Huinink\}, W.W. and H.H. Hansen and H.M. Pinedo and M. Hansen and J. Renard and \{van Glabbeke\}, M.",

year = "1986",

language = "English",

volume = "22",

pages = "697--699",

journal = "European journal of cancer \& clinical oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "6",

}

Bruntsch, U, Dodion, P, ten Bokkel Huinink, WW, Hansen, HH, Pinedo, HM, Hansen, M, Renard, J & van Glabbeke, M 1986, 'Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group', European journal of cancer & clinical oncology, vol. 22, no. 6, pp. 697-699.

Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group. / Bruntsch, U.; Dodion, P.; ten Bokkel Huinink, W.W. et al.
In: European journal of cancer & clinical oncology, Vol. 22, No. 6, 1986, p. 697-699.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Primary resistance of renal adenocarcinoma to 1,2,4 triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent phase II study of the EORTC Early Clinical Trials Group

AU - Bruntsch, U.

AU - Dodion, P.

AU - ten Bokkel Huinink, W.W.

AU - Hansen, H.H.

AU - Pinedo, H.M.

AU - Hansen, M.

AU - Renard, J.

AU - van Glabbeke, M.

PY - 1986

Y1 - 1986

M3 - Article

SN - 0277-5379

VL - 22

SP - 697

EP - 699

JO - European journal of cancer & clinical oncology

JF - European journal of cancer & clinical oncology

IS - 6

ER -